News and Trends 9 Mar 2023 Iktos raises €15.5M to expand AI drug discovery technologies Iktos, a company specializing in artificial intelligence (AI) for new drug discovery, has closed a €15.5 million ($16.4 million) Series A financing co-led by new investors M Ventures and Debiopharm Innovation Fund with participation from Omnes Capital. This financing will enable Iktos to further develop its AI and drug discovery capabilities and expand its existing SaaS software […] March 9, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Mar 2023 Ampersand Biomedicines launched to develop drugs that only work at disease sites Flagship Pioneering has created Ampersand Biomedicines, a company creating programmable medicines that are intended to be safer, more tolerable, and effective by acting at the site of disease. Flagship Pioneering has initially committed $50 million to advance the company’s Address, Navigate, Design (AND) platform and develop an initial pipeline of medicines across a range of […] March 9, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Mar 2023 Noema Pharma raises $112 million in Series B financing Noema Pharma, a Swiss clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, has closed an oversubscribed Series B financing round, raising CHF 103 million ($112 million) from new and existing investors. The round was co-led by leading European healthcare focused investment firms Forbion and Jeito Capital. UPMC Enterprises and an additional new investor […] March 8, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Mar 2023 Genomic medicine company Chroma raises $135M Chroma Medicine, Inc., a genomic medicine company advancing single-dose epigenetic editing therapeutics, has completed a $135 million Series B financing. The funding was led by GV (Google Ventures), with participation from additional new investors ARCH Venture Partners, DCVC Bio, Mubadala Capital, Sixth Street, and all existing investors, including Alexandria Venture Investments, Atlas Venture, Casdin Capital, […] March 2, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Mar 2023 Ten new companies join BioInnovation Institute’s Venture Lab program BioInnovation Institute (BII), an international non-profit foundation incubating and accelerating life science research, has added 10 new companies to its Venture Lab acceleration program for early-stage companies. The cohort is aligned with BioInnovation Institute’s focus on supporting innovative early-stage start-ups within human and planetary health. The 12-month program is designed to support start-up companies with […] March 2, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Opinion 28 Feb 2023 Life changing treatments for rare disease – a beacon of hope By Sander Slootweg, managing partner, Forbion More than 300 million people around the globe are affected by a rare disease. This number does not even take into account the impact on these individuals’ support units that includes family, friends and caregivers. A rare disease is defined as a disease that affects no more than 1 […] February 28, 2023 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 24 Feb 2023 Resalis Therapeutics receives €10M to develop obesity and NAFLD treatment Resalis Therapeutics has completed a seed financing round of €10 million to establish a non-coding RNA (ncRNA)-based therapeutic approach for the treatment of metabolic diseases. The funding will support the finalization of IND-enabling studies for the Resalis Therapeutics’ lead program, RES-010, which Resalis will initially develop as a novel treatment for obesity and nonalcoholic fatty […] February 24, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Feb 2023 Italian life sciences fund hits €175M Panakès Partners, an Italian venture capital firm in the life sciences sector, has closed its Purple Fund with a total of €175 million ($185.4 million). Panakès Purple Fund is currently the largest Italian Venture Capital Fund, in the investment phase, dedicated to life sciences, with an investment focus in Italy and Europe, as well as […] February 23, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Feb 2023 Hemab Therapeutics receives $135M to address bleeding and thrombotic disorders Hemab Therapeutics, a clinical-stage biotechnology company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, has announced the closing of an oversubscribed $135 million Series B financing. Access Biotechnology led the round, with participation from new investors Deep Track Capital, Avoro Ventures, Invus, Rock Springs Capital, and Maj Invest Equity, as well […] February 21, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Feb 2023 Avilar Therapeutics financing up to $75M to boost extracellular protein degraders pipeline Avilar Therapeutics has raised additional funding with an expanded syndicate of new investors to support advancing a pipeline of first-in-class extracellular protein degraders. The new financing takes the company’s total to $75 million. The seed round had initial funding from Avilar’s founding investor, RA Capital Management, and now includes participation by new investors Sanofi Ventures, […] February 17, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Feb 2023 Maxion Therapeutics raises $16M to target GPCRs Biotechnology company Maxion Therapeutics has completed its $16 million Series A financing. The funds will be used to support the development of novel biologics targeting ion channels and G-protein-coupled receptors (GPCRs) via Maxion’s proprietary, patent-protected KnotBody platform. Ion channels and GPCRs are critical cell surface proteins involved in a wide range of previously untreatable or […] February 16, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Feb 2023 Disc Medicine raises $62.5M for hematology programs Disc Medicine, Inc., a U.S. clinical-stage biopharma company focused on the discovery, development and commercialization of treatments for patients suffering from serious hematologic diseases, has entered into a securities purchase agreement with investors resulting in an aggregate $62.5 million in gross proceeds through a registered direct offering. The financing was led by Bain Capital Life […] February 14, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email